Khondrion
Manufacturing · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Transistorweg 5c M Building, Nijmegen, G...Phone Number
+31 247635000Website
www.khondrion.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Khondrion
Khondrion is a clinical-stage biopharmaceutical company leading the development of innovative therapies targeting primary mitochondrial diseases (PMDs). With a focus on first-in-class treatments that address the devastating effects of mitochondrial dysfunction, Khondrion aims to transform the lives of patients living with these highly impactful multisystem disorders.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Khondrion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Khondrion launches new products
Check if Khondrion has recently received funding, and reach out quickly before it becomes old news!
Click to see if Khondrion had a recent Job posting/layoffs
Check out if Khondrion is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Khondrion
Earning: See what the market has to say on Khondrion recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Khondrion, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Khondrion has new funding data
Recommended Actions
Find VP level buyers at Khondrion
Find 2 more new buyers
Company Profile Activity
Activity Insights
Khondrion is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Khondrion is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Khondrion.
Khondrion financials insights
Gather financial insights about Khondrion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$5.7M
Khondrion Tech Stack
A closer look at the technologies used by Khondrion
See more technologies
Khondrion News & Media
Khondrion Secures Up To €5M
Khondrion, a Nijmegen, the Netherlands-based clinical-stage biopharmaceutical company developing therapies for primary mitochondrial disease (PMD), received an Innovation Credit of up to €5M from the Netherlands Enterprise Agency. This government funding, matched by an investment from private backers, will fund Wave 1 of the company’s pivotal Phase 3 clinical trial of sonlicromanol. Sonlicromanol is a first-in-class small-molecule candidate therapy for […] The post Khondrion Secures Up To €5M apKhondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease
Government support, alongside private investments, funds first wave of pivotal Phase 3 trial of sonlicromanol for m.3243A>G Primary Mitochondrial Disease (PMD) NIJMEGEN, Netherlands, May 6, 2025 /PRNewswire/ -- Khondrion, a clinical-stage biopharmaceutical company pioneering therapies for...UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease (PMD).Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease
Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Khondrion
Sign Up For FreeTo access detailed company insights
Khondrion is a clinical-stage biopharmaceutical company leading the development of innovative therapies targeting primary mitochondrial diseases (PMDs). With a focus on first-in-class treatments that address the devastating effects of mitochondrial dysfunction, Khondrion aims to transform the lives of patients living with these highly impactful mu... Read More
